We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

19 hedge funds and large institutions have $5.81M invested in Tonix Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

189% more capital invested

Capital invested by funds: $2.01M → $5.81M (+$3.8M)

36% more funds holding

Funds holding: 14 → 19 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

Holders
19
Holders Change
+5
Holders Change %
+35.71%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
7
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.36M
2
Marshall Wace
Marshall Wace
United Kingdom
+$1.21M
3
AC
Armistice Capital
New York
+$1.17M
4
SM
Sabby Management
Florida
+$929K
5
ACM
Altium Capital Management
New York
+$272K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$37K
2
JP Morgan Chase
JP Morgan Chase
New York
-$11.3K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$9.66K
4
BlackRock
BlackRock
New York
-$3.22K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.52M +$1.17M +725 +160%
SM
2
Sabby Management
Florida
$1.25M +$929K +577 +148%
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$1.09M +$1.36M +845 New
Marshall Wace
4
Marshall Wace
United Kingdom
$960K +$1.21M +750 New
RA
5
Rosalind Advisors
Ontario, Canada
$363K +$454K +282 New
ACM
6
Altium Capital Management
New York
$218K +$272K +169 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$163K +$4.83K +3 +2%
Renaissance Technologies
8
Renaissance Technologies
New York
$97K +$8.05K +5 +7%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$43K -$9.66K -6 -15%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$37K +$38.6K +24 +480%
BlackRock
11
BlackRock
New York
$16.9K -$3.22K -2 -13%
State Street
12
State Street
Massachusetts
$12.6K – – –
Millennium Management
13
Millennium Management
New York
$10.9K +$3.22K +2 +33%
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$8K – – –
Northern Trust
15
Northern Trust
Illinois
$6.57K – – –
Morgan Stanley
16
Morgan Stanley
New York
$6.42K +$3.22K +2 +67%
GS
17
GTS Securities
New York
$5.67K +$6.44K +4 New
FWTB
18
First Western Trust Bank
Colorado
$4.16K +$4.83K +3 New
CCM
19
Crew Capital Management
Ohio
$4.03K +$4.83K +3 New
Osaic Holdings
20
Osaic Holdings
Arizona
$265 – – –
Wells Fargo
21
Wells Fargo
California
$74 – – –
NL
22
NVWM LLC
Pennsylvania
$56 – – –
GRP
23
Global Retirement Partners
California
$20 – – –
Bank of America
24
Bank of America
North Carolina
$16 – – –
FWM
25
Focused Wealth Management
New York
$15 – – –
1
2

TNXP Hedge Fund Activity: Q4 2023 in Review

19 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q4 2023, worth a combined $5.81M — up 189% from $2.01M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TNXP positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $1.36M. The largest seller was Virtu Financial, exiting entirely with an estimated $37K sold.

  • 19 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q4 2023, up from 14 in Q3 2023.
  • Funds reported $5.81M of Tonix Pharmaceuticals stock for Q4 2023, up 189% quarter-over-quarter.
  • 7 funds opened new Tonix Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of +5 holders.
  • The largest Tonix Pharmaceuticals buyer in Q4 2023 was Alyeska Investment Group, an estimated $1.36M added.
  • The largest Tonix Pharmaceuticals seller in Q4 2023 was Virtu Financial, an estimated $37K sold.

Based on aggregated 13F filings for Q4 2023.